{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T01:25:12Z","timestamp":1770427512522,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,8,18]],"date-time":"2004-08-18T00:00:00Z","timestamp":1092787200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>In order to confirm therapeutic effects of topiramate on posttraumatic stress disorder (PTSD) observed in a prior study, a new prospective, open-label study was conducted to examine acute responses in chronic, nonhallucinatory PTSD.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Thirty-three consecutive newly recruited civilian adult outpatients (mean age 46 years, 85% female) with DSM-IV-diagnosed chronic PTSD, excluding those with concurrent auditory or visual hallucinations, received topiramate either as monotherapy (n = 5) or augmentation (n = 28). The primary measure was a change in the PTSD Checklist-Civilian Version (PCL-C) score from baseline to 4 weeks, with response defined as a \u2265 30% reduction of PTSD symptoms.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>For those taking the PCL-C at both baseline and week 4 (n = 30), total symptoms declined by 49% at week 4 (paired <jats:italic>t<\/jats:italic>-test, <jats:italic>P<\/jats:italic> &lt; 0.001) with similar subscale reductions for reexperiencing, avoidance\/numbing, and hyperarousal symptoms. The response rate at week 4 was 77%. Age, sex, bipolar comorbidity, age at onset of PTSD, duration of symptoms, severity of baseline PCL-C score, and monotherapy versus add-on medication administration did not predict reduction in PTSD symptoms. Median time to full response was 9 days and median dosage was 50 mg\/day.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Promising open-label findings in a new sample converge with findings of a previous study. The use of topiramate for treatment of chronic PTSD, at least in civilians, warrants controlled clinical trials.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/1471-244x-4-24","type":"journal-article","created":{"date-parts":[[2004,8,21]],"date-time":"2004-08-21T06:23:00Z","timestamp":1093069380000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder"],"prefix":"10.1186","volume":"4","author":[{"given":"Jeffrey L","family":"Berlant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,8,18]]},"reference":[{"issue":"Suppl 17","key":"63_CR1","first-page":"16","volume":"62","author":"N Breslau","year":"2001","unstructured":"Breslau N: The epidemiology of posttraumatic stress disorder: what is the extent of the problem?. J Clin Psychiatry. 2001, 62 (Suppl 17): 16-22.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 9","key":"63_CR2","first-page":"16","volume":"58","author":"BA van der Kolk","year":"1997","unstructured":"van der Kolk BA: The psychobiology of posttraumatic stress disorder. J Clin Psychiatry. 1997, 58 (Suppl 9): 16-24.","journal-title":"J Clin Psychiatry"},{"key":"63_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00002826-200207000-00006","volume":"25","author":"I Iancu","year":"2002","unstructured":"Iancu I, Rosen Y, Moshe K: Antiepileptic drugs in posttraumatic stress disorder. Clin Neuropharmacol. 2002, 25: 225-229. 10.1097\/00002826-200207000-00006.","journal-title":"Clin Neuropharmacol"},{"key":"63_CR4","first-page":"41","volume":"10","author":"J Berlant","year":"2003","unstructured":"Berlant J: Antiepileptic treatment of posttraumatic stress disorder. Primary Psychiatry. 2003, 10: 41-49.","journal-title":"Primary Psychiatry"},{"issue":"Suppl 9","key":"63_CR5","first-page":"29","volume":"58","author":"JR Davidson","year":"1997","unstructured":"Davidson JR: Biological therapies for posttraumatic stress disorder: an overview. J Clin Psychiatry. 1997, 58 (Suppl 9): 29-32.","journal-title":"J Clin Psychiatry"},{"key":"63_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4088\/JCP.v63n0104","volume":"63","author":"J Berlant","year":"2002","unstructured":"Berlant J, van Kammen DP: Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002, 63: 15-20.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 1","key":"63_CR7","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1111\/j.1528-1157.2000.tb06048.x","volume":"41","author":"RJ DeLorenzo","year":"2000","unstructured":"DeLorenzo RJ, Sombati S, Coulter DA: Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia. 2000, 41 (Suppl 1): S40-44.","journal-title":"Epilepsia"},{"key":"63_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0304-3940(97)00543-0","volume":"231","author":"C Zona","year":"1997","unstructured":"Zona C, Ciotti MT, Avoli M: Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett. 1997, 231: 123-126. 10.1016\/S0304-3940(97)00543-0.","journal-title":"Neurosci Lett"},{"issue":"Suppl 1","key":"63_CR9","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1111\/j.1528-1157.2000.tb02166.x","volume":"41","author":"MJ McLean","year":"2000","unstructured":"McLean MJ, Bukhari AA, Wamil AW: Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia. 2000, 41 (Suppl 1): S21-24.","journal-title":"Epilepsia"},{"key":"63_CR10","first-page":"960","volume":"288","author":"S Taverna","year":"1999","unstructured":"Taverna S, Sancini G, Mantegazza M, Franceschetti S, Avanzini G: Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther. 1999, 288: 960-968.","journal-title":"J Pharmacol Exp Ther"},{"key":"63_CR11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/sj.bjp.0702096","volume":"125","author":"SP Wu","year":"1998","unstructured":"Wu SP, Tsai JJ, Gean PW: Frequency-dependent inhibition of neuronal activity by topiramate in rat hippocampal slices. Br J Pharmacol. 1998, 125: 826-832.","journal-title":"Br J Pharmacol"},{"issue":"Suppl 1","key":"63_CR12","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1111\/j.1528-1157.2000.tb02173.x","volume":"41","author":"X Zhang","year":"2000","unstructured":"Zhang X, Velumian AA, Jones OT, Carlen PL: Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia. 2000, 41 (Suppl 1): S52-60.","journal-title":"Epilepsia"},{"key":"63_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0920-1211(97)00045-4","volume":"28","author":"HS White","year":"1997","unstructured":"White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH: Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 1997, 28: 167-179. 10.1016\/S0920-1211(97)00045-4.","journal-title":"Epilepsy Res"},{"issue":"Suppl 1","key":"63_CR14","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1111\/j.1528-1157.2000.tb02165.x","volume":"41","author":"HS White","year":"2000","unstructured":"White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH: Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 2000, 41 (Suppl 1): S17-20.","journal-title":"Epilepsia"},{"key":"63_CR15","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/j.1528-1157.2000.tb02164.x","volume":"41","author":"JW Gibbs III","year":"2000","unstructured":"Gibbs JW, Sombati S, DeLorenzo RJ, Coulter DA: Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000, 41: S10-S16.","journal-title":"Epilepsia"},{"key":"63_CR16","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1111\/j.1528-1157.2000.tb02171.x","volume":"41","author":"S Skradski","year":"2000","unstructured":"Skradski S, White HS: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia. 2000, 41: S45-S47.","journal-title":"Epilepsia"},{"key":"63_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0920-1211(95)00105-0","volume":"24","author":"A Wauquier","year":"1996","unstructured":"Wauquier A, Zhou S: Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res. 1996, 24: 73-77. 10.1016\/0920-1211(95)00105-0.","journal-title":"Epilepsy Res"},{"key":"63_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0920-1211(98)00021-7","volume":"31","author":"K Amano","year":"1998","unstructured":"Amano K, Hamada K, Yagi K, Seino M: Antiepileptic effects of topiramate on amygdaloid kindling in rats. Epilepsy Res. 1998, 31: 123-128. 10.1016\/S0920-1211(98)00021-7.","journal-title":"Epilepsy Res"},{"key":"63_CR19","unstructured":"DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 1994, Washington, DC: American Psychiatric Association, 4"},{"key":"63_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/(SICI)1520-6394(1997)5:1<34::AID-DA6>3.0.CO;2-5","volume":"5","author":"MB Hamner","year":"1997","unstructured":"Hamner MB: Psychotic features and combat-associated PTSD. Depress Anxiety. 1997, 5: 34-38. 10.1002\/(SICI)1520-6394(1997)5:1<34::AID-DA6>3.0.CO;2-5.","journal-title":"Depress Anxiety"},{"key":"63_CR21","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/S0006-3223(98)00301-1","volume":"45","author":"MB Hamner","year":"1999","unstructured":"Hamner MB, Frueh BC, Ulmer HG, Arana GW: Psychotic features and illness severity in combat veterans with chronic posttraumatic stress disorder. Biol Psychiatry. 1999, 45: 846-852. 10.1016\/S0006-3223(98)00301-1.","journal-title":"Biol Psychiatry"},{"key":"63_CR22","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/0005-7967(96)00033-2","volume":"34","author":"EB Blanchard","year":"1996","unstructured":"Blanchard EB, Jones-Alexander J, Buckley TC, Forneris CA: Psychometric properties of the PTSD Checklist (PCL). Behav Res Ther. 1996, 34: 669-673. 10.1016\/0005-7967(96)00033-2.","journal-title":"Behav Res Ther"},{"key":"63_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/da.1029","volume":"13","author":"FW Weathers","year":"2001","unstructured":"Weathers FW, Keane TM, Davidson JR: Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety. 2001, 13: 132-156. 10.1002\/da.1029.","journal-title":"Depress Anxiety"},{"key":"63_CR24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0033-3182(86)72590-5","volume":"27","author":"S Lipper","year":"1986","unstructured":"Lipper S, Davidson JR, Grady TA, Edinger JD, Hammett EB, Mahorney SL, Cavenar JO: Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics. 1986, 27: 849-854.","journal-title":"Psychosomatics"},{"key":"63_CR25","first-page":"361","volume":"52","author":"FA Fesler","year":"1991","unstructured":"Fesler FA: Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry. 1991, 52: 361-364.","journal-title":"J Clin Psychiatry"},{"key":"63_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1023\/A:1024797014210","volume":"12","author":"RD Clark","year":"1999","unstructured":"Clark RD, Canive JM, Calais LA, Qualls CR, Tuason VB: Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress. 1999, 12: 395-401. 10.1023\/A:1024797014210.","journal-title":"J Trauma Stress"},{"key":"63_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/00004714-200202000-00021","volume":"22","author":"F Petty","year":"2002","unstructured":"Petty F, Davis LL, Nugent AL, Kramer GL, Teten A, Schmitt A, Stone RC: Valproate therapy for chronic, combat-induced posttraumatic stress disorder. J Clin Psychopharmacol. 2002, 22: 100-101. 10.1097\/00004714-200202000-00021.","journal-title":"J Clin Psychopharmacol"},{"key":"63_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/01.jcp.0000106234.36344.a4","volume":"24","author":"C Otte","year":"2004","unstructured":"Otte C, Wiedemann K, Yassouridis A, Kellner M: Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study. J Clin Psychopharmacol. 2004, 24: 106-108. 10.1097\/01.jcp.0000106234.36344.a4.","journal-title":"J Clin Psychopharmacol"},{"key":"63_CR29","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S0006-3223(99)00011-6","volume":"45","author":"MA Hertzberg","year":"1999","unstructured":"Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM, Davidson JR: A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999, 45: 1226-1229. 10.1016\/S0006-3223(99)00011-6.","journal-title":"Biol Psychiatry"},{"key":"63_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3109\/10401230109148960","volume":"13","author":"MB Hamner","year":"2001","unstructured":"Hamner MB, Brodrick PS, Labbate LA: Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001, 13: 141-146. 10.1023\/A:1012281424057.","journal-title":"Ann Clin Psychiatry"},{"issue":"Suppl 17","key":"63_CR31","first-page":"60","volume":"62","author":"JL Berlant","year":"2001","unstructured":"Berlant JL: Topiramate in posttraumatic stress disorder: preliminary clinical observations. J Clin Psychiatry. 2001, 62 (Suppl 17): 60-63.","journal-title":"J Clin Psychiatry"},{"key":"63_CR32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1017\/S0317167100021879","volume":"24","author":"CL Corman","year":"1997","unstructured":"Corman CL, Leung NM, Guberman AH: Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci. 1997, 24: 240-244.","journal-title":"Can J Neurol Sci"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-4-24.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-4-24\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-4-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-4-24.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:51:01Z","timestamp":1728305461000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-4-24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,18]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,12]]}},"alternative-id":["63"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-4-24","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,18]]},"assertion":[{"value":"7 June 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"24"}}